CompletedNCT03154359
Atomoxetine Levels and Response Across CYP2D6 Groups in Children With ADHD
About this title
Read the official source — NCT03154359Observational studyAges 6–18United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
- Listed locations
- Kansas CitySee all locations and recruitment
Study information
Study start dateStarted: December 12, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Children's Mercy Hospital Kansas City
- Sponsor type
- Hospital / academic medical center
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT03154359
- Official title
Show the full official title
An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate and Poor Metabolizers in Children With Attention Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kansas City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Children's Mercy Hospital Kansas City, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
